Literature DB >> 28080053

Lipid-Drug Conjugate for Enhancing Drug Delivery.

Danielle Irby1, Chengan Du1, Feng Li1.   

Abstract

Lipid-drug conjugates (LDCs) are drug molecules that have been covalently modified with lipids. The conjugation of lipids to drug molecules increases lipophilicity and also changes other properties of drugs. The conjugates demonstrate several advantages including improved oral bioavailability, improved targeting to the lymphatic system, enhanced tumor targeting, and reduced toxicity. Based on the chemical nature of drugs and lipids, various conjugation strategies and chemical linkers can be utilized to synthesize LDCs. Linkers and/or conjugation methods determine how drugs are released from LDCs and are critical for the optimal performance of LDCs. In this review, different lipids used for preparing LDCs and various conjugation strategies are summarized. Although LDCs can be administered without a delivery carrier, most of them are loaded into appropriate delivery systems. The lipid moiety in the conjugates can significantly enhance drug loading into hydrophobic components of delivery carriers and thus generate formulations with high drug loading and superior stability. Different delivery carriers such as emulsions, liposomes, micelles, lipid nanoparticles, and polymer nanoparticles are also discussed in this review.

Entities:  

Keywords:  chemical bonds; conjugation; drug delivery; lipid; prodrug

Mesh:

Substances:

Year:  2017        PMID: 28080053      PMCID: PMC5477224          DOI: 10.1021/acs.molpharmaceut.6b01027

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  131 in total

1.  Prodrugs of pioglitazone for extended-release (XR) injectable formulations.

Authors:  Carlos N Sanrame; Julius F Remenar; Laura C Blumberg; Julie Waters; Reginald L Dean; Nan Dong; Kristi Kriksciukaite; Peixin Cao; Orn Almarsson
Journal:  Mol Pharm       Date:  2014-09-09       Impact factor: 4.939

2.  Antitumor activity of new liposomal prodrug of mitomycin C in multidrug resistant solid tumor: insights of the mechanism of action.

Authors:  Samuel Zalipsky; Maha Saad; Radwan Kiwan; Elizabeth Ber; Ning Yu; Tamara Minko
Journal:  J Drug Target       Date:  2007 Aug-Sep       Impact factor: 5.121

3.  Lysosomal delivery of a lipophilic gemcitabine prodrug using novel acid-sensitive micelles improved its antitumor activity.

Authors:  Saijie Zhu; Dharmika S P Lansakara-P; Xinran Li; Zhengrong Cui
Journal:  Bioconjug Chem       Date:  2012-04-18       Impact factor: 4.774

4.  Novel therapeutic nano-particles (lipocores): trapping poorly water soluble compounds.

Authors:  W R Perkins; I Ahmad; X Li; D J Hirsh; G R Masters; C J Fecko; J Lee; S Ali; J Nguyen; J Schupsky; C Herbert; A S Janoff; E Mayhew
Journal:  Int J Pharm       Date:  2000-04-25       Impact factor: 5.875

5.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Authors:  Jürgen Soutschek; Akin Akinc; Birgit Bramlage; Klaus Charisse; Rainer Constien; Mary Donoghue; Sayda Elbashir; Anke Geick; Philipp Hadwiger; Jens Harborth; Matthias John; Venkitasamy Kesavan; Gary Lavine; Rajendra K Pandey; Timothy Racie; Kallanthottathil G Rajeev; Ingo Röhl; Ivanka Toudjarska; Gang Wang; Silvio Wuschko; David Bumcrot; Victor Koteliansky; Stefan Limmer; Muthiah Manoharan; Hans-Peter Vornlocher
Journal:  Nature       Date:  2004-11-11       Impact factor: 49.962

6.  Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin.

Authors:  Khalid Abu Ajaj; Ralph Graeser; Felix Kratz
Journal:  Breast Cancer Res Treat       Date:  2012-01-08       Impact factor: 4.872

7.  Pharmacologic Studies of a Prodrug of Mitomycin C in Pegylated Liposomes (Promitil(®)): High Stability in Plasma and Rapid Thiolytic Prodrug Activation in Tissues.

Authors:  Yasmine Amitay; Hilary Shmeeda; Yogita Patil; Jenny Gorin; Dina Tzemach; Lidia Mak; Patricia Ohana; Alberto Gabizon
Journal:  Pharm Res       Date:  2015-11-16       Impact factor: 4.200

8.  Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics.

Authors:  José L Arias; L Harivardhan Reddy; Mohammad Othman; Brigitte Gillet; Didier Desmaële; Fatima Zouhiri; Franco Dosio; Ruxandra Gref; Patrick Couvreur
Journal:  ACS Nano       Date:  2011-01-28       Impact factor: 15.881

9.  Anti-angiogenesis therapy in the Vx2 rabbit cancer model with a lipase-cleavable Sn 2 taxane phospholipid prodrug using α(v)β₃-targeted theranostic nanoparticles.

Authors:  Dipanjan Pan; Anne H Schmieder; Kezheng Wang; Xiaoxia Yang; Angana Senpan; Grace Cui; Kendall Killgore; Benjamin Kim; John S Allen; Huiying Zhang; Shelton D Caruthers; Baozhong Shen; Samuel A Wickline; Gregory M Lanza
Journal:  Theranostics       Date:  2014-03-11       Impact factor: 11.556

10.  Design and synthesis of new cholesterol-conjugated 5-Fluorouracil: a novel potential delivery system for cancer treatment.

Authors:  Awwad A Radwan; Fares K Alanazi
Journal:  Molecules       Date:  2014-08-26       Impact factor: 4.411

View more
  37 in total

1.  Observation-driven inquiry: Raman spectroscopic imaging illuminates cancer lipid metabolism.

Authors:  Aurelio Lorico; Germana Rappa; Denis Corbeil; Thuc T Le
Journal:  Stem Cell Investig       Date:  2017-05-26

2.  Reduction toxicity of Amphotericin B through loading into a novel nanoformulation of anionic linear globular dendrimer for improve treatment of leishmania major.

Authors:  Tahereh Zadeh Mehrizi; Mehdi Shafiee Ardestani; Ali Khamesipour; Mostafa Haji Molla Hoseini; Nariman Mosaffa; Ali Anissian; Amitis Ramezani
Journal:  J Mater Sci Mater Med       Date:  2018-07-28       Impact factor: 3.896

3.  Delivery of a model lipophilic membrane cargo to bone marrow via cell-derived microparticles.

Authors:  Chunyan Yang; Fangfang Chen; Ping Ren; Laren Lofchy; Chun Wan; Jingshi Shen; Guankui Wang; Hanmant Gaikwad; Jessica Ponder; Craig T Jordan; Robert Scheinman; Dmitri Simberg
Journal:  J Control Release       Date:  2020-07-16       Impact factor: 9.776

4.  Synthesis of a long acting nanoformulated emtricitabine ProTide.

Authors:  Dhruvkumar Soni; Aditya N Bade; Nagsen Gautam; Jonathan Herskovitz; Ibrahim M Ibrahim; Nathan Smith; Melinda S Wojtkiewicz; Bhagya Laxmi Dyavar Shetty; Yazen Alnouti; JoEllyn McMillan; Howard E Gendelman; Benson J Edagwa
Journal:  Biomaterials       Date:  2019-08-20       Impact factor: 12.479

5.  Pharmacokinetic and Chemical Synthesis Optimization of a Potent d-Peptide HIV Entry Inhibitor Suitable for Extended-Release Delivery.

Authors:  Joseph S Redman; J Nicholas Francis; Robert Marquardt; Damon Papac; Alan L Mueller; Debra M Eckert; Brett D Welch; Michael S Kay
Journal:  Mol Pharm       Date:  2018-02-22       Impact factor: 4.939

6.  Nanoparticulate tablet dosage form of lisofylline-linoleic acid conjugate for type 1 diabetes: in situ single-pass intestinal perfusion (SPIP) studies and pharmacokinetics in rat.

Authors:  Kishan S Italiya; Arihant K Singh; Deepak Chitkara; Anupama Mittal
Journal:  AAPS PharmSciTech       Date:  2021-03-24       Impact factor: 3.246

7.  Iron oxide nanoparticle targeted chemo-immunotherapy for triple negative breast cancer.

Authors:  Qin Gxin Mu; Guanyou Lin; Mike Jeon; Hui Wang; Fei-Chien Chang; Richard A Revia; John Yu; Miqin Zhang
Journal:  Mater Today (Kidlington)       Date:  2021-09-07       Impact factor: 31.041

8.  Computational and Experimental Approaches to Investigate Lipid Nanoparticles as Drug and Gene Delivery Systems.

Authors:  Chun Chan; Shi Du; Yizhou Dong; Xiaolin Cheng
Journal:  Curr Top Med Chem       Date:  2021       Impact factor: 3.295

Review 9.  Tumor-Associated Fibroblast-Targeting Nanoparticles for Enhancing Solid Tumor Therapy: Progress and Challenges.

Authors:  Wenpan Li; Nicholas Little; Jonghan Park; Cole Alexander Foster; Jiawei Chen; Jianqin Lu
Journal:  Mol Pharm       Date:  2021-07-14       Impact factor: 4.939

10.  Synthesis of secondary and tertiary amides without coupling agents from amines and potassium acyltrifluoroborates (KATs).

Authors:  Anne Schuhmacher; Tomoya Shiro; Sarah J Ryan; Jeffrey W Bode
Journal:  Chem Sci       Date:  2020-03-10       Impact factor: 9.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.